Expanded Access Program With Nivolumab to Treat Melanoma

N/ANo Longer AvailableNCT02142218

Bristol-Myers Squibb

Overview

The purpose of this program is to provide treatment with nivolumab to subjects with Stage III or Stage IV advanced melanoma.

Study Type

EXPANDED_ACCESS

Conditions

Stage III (Unresectable) or Stage IV Advanced Melanoma

Interventions

NivolumabDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: * ECOG Performance Status of 0-1 * Histologically confirmed malignant melanoma * Progressed on or after treatment with an anti-CTLA4 Exclusion Criteria: * Active brain metastases * Life Expectancy \<6 weeks * Subjects who received prior therapy targeting T-cell costimulation or checkpoint pathways except for Anti CTLA-4 therapy * Subjects with autoimmune disease

Locations (80)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Local Institution

Mobile, Alabama, United States

Southern Cancer Center Pc

Mobile, Alabama, United States

Local Institution

Encinitas, California, United States

Local Institution

Washington D.C., District of Columbia, United States

Lynn Cancer Institute At Boca Raton Regional Hospital

Boca Raton, Florida, United States

Cancer Specialists Of North Florida

Jacksonville, Florida, United States

Mount Sinai Comprehensive Cancer Center

Miami Beach, Florida, United States

Florida Hospital

Orlando, Florida, United States

Winship Cancer Institute

Atlanta, Georgia, United States

Summit Cancer Care

Savannah, Georgia, United States

...and 70 more locations